GNCA - Earnings call transcript Q3 2021 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Genocea Third Quarter 2021 Conference Call. At this time all participants are in a listen-only mode.

Following a form of remarks, we will open the call up for your questions. Please be advised to this call is being recorded by the company’s request. At this time, I would like to turn over to Mr. Advisors. LifeSci of Ferry Dan Please go sir. ahead,

Dan Ferry

at Thank issued a operator. plan discuss is And Investors the good we today, to available release This Earlier everyone. today. under press we the tab. morning, topics you, genocea.com release outlines that

call will President Genocea’s and today, remarks, Chief will results. then Chip; the Davis, review brief the provide we CEO, Financial Chief your Clark, the up prepared and Diantha, financial Genocea’s update; Flechtner, for the company’s be answer Chip Officer, the will will a Officer; During corporate Diantha And Duvall, Q&A. Medical Chief open call to questions. Officer, Jessica and Tom Scientific After available

to I Before Genocea. many are directed statements, updates XX-K Commission. to the pass reports and risk factors It periodic Form to the the such impact events as future that to to be to my to performance, protection made Private events Genocea’s Participants business the set could and would forth prospects now otherwise. XXXX. everyone result pleasure of over or the relating Chip. are other the on XXXX future plans in or under as remind outcomes statements and due with Genocea from factors expected expressly All report of duty like forward-looking Securities differ harbor control is a we the safe statements may include future Genocea’s filed call annual the results Securities future materially to during to begin, Reform of those statements Litigation Exchange any of provided whether or defined Act. to disclaims Actual forward-looking forecasts forward-looking call this beyond intended provide its Reform Act by conference subject new information,

Chip Clark

for Genocea’s GEN-XXX, our to notably, Dan. joining trial thank today. program. clinical TiTAN™ excited we our are about And you share I am all Most you with clinical progress us Thanks, pleased for lead today.

trial the a ATLAS™ we’re cell taken study key and and peripheral better targets their Patients Genocea’s GEN-XXX persistence tumors. success. monotherapy. I expanding may prioritized refractory TiTAN™ CDX designed also blood therapy, a Phase may MPT neoantigens peripheral give as from the which initially reminder, T-cells evaluate T-cells will the X/Xa the testing checkpoint to you GEN-XXX other using solid accessible is efficacy of easily hold for better and is inhibitor GEN-XXX to safety clinical preferentially platform proliferation, that CDX remind our T-cell tolerability, therapy, T split and and As blood receive patient doses believe followed cost either daily with and dose over GEN-XXX multiple neoantigen-targeted regimen, in and a proprietary tumor intermediate by IL-X, efficacy, We therapy, by conventional into by to lymphodepletion patient’s single we dose preceded lymphodepletion by as or or a adopted GEN-XXX words, In T-cell therapies. T-cells doses. no that believe with accessibility and IL-X advantages other high followed T-cell people

with And from five next first we progress the on active more expect online and proprietary of come to or progress have with now clinical substantive make sites quarter to Based this imminently. in small reliably early to process continue We initial product. drug PLANET data patients year. subset now yielding our three a second

through Officer Board our so Board as of we proud ATLAS to SITC continue research disease demonstrate Genocea multiple application Senior at efforts. President our treatments. now inhibition Jennifer close extensive Chief team to novel compliment for also with and autoimmune and Herron, Diantha These next neoantigen capabilities the of development agility through Vice quarter members. GEN-XXX, the are to to showcase candidate, presentations our Annual nicely poster clinical call pass and of clinical we I’m update response the adjuvanted am Diantha? Directors. to they the to welcome of differentiated call the tenacity these to for pleased experiences month’s up and potential those will our oncology Her peptide XXXX presentations our am and my questions. summarize platform I’ll and Commercial saying at neoantigen from of I have this vaccine data brief research immunogenicity financials long-term part I to that ADC over We pleased by other that opening going additional before this Therapeutics their also selection Meeting. continue

Diantha Duvall

the good at December you, million compared and of XX, Thank equivalents $XX.X million $XX.X and Chip, quarter morning, ended with everyone. cash XXXX. with cash We

ended Our are XX, the XXXX quarter for as operating results September follows.

for in XXXX $X.X net loss months ended the to for September same period XXXX. $X.X was Our the compared three XX, million million

our million expenses $X.X million same million in R&D growth for compared same loss million, to in XXXX. compared ended net costs. the XX, the periods same team for manufacturing ended were to expenses XXXX for compared expenses months for million $X.X XXXX. compared and XXXX teams period $X.X in mainly decreased XXXX million XX, were months million due for XXXX. XX, $XX.X costs. $XX.X increase same mainly due fair September in the research Other $XX.X $XX.X XXXX Our offset period same months due $XX.X the million million XXXX. to G&A income period months nine for to in the growth period with September the September million the ended clinical connection ended million, XX, warrants XXXX was for period million placement. the expenses The the the September increase September G&A quarter $X.X issued period nine manufacturing the $X.X nine in period $X.X for The to both for for the expenses to the partially million is for is same XXXX. periods in September is was liability-classified non-cash the September in for expenses $XX.X income in nine for private compared XXXX internal the were compared to increase in $X.X XXXX. for in ended other ended and income of Other R&D value GEN-XXX $XX.X XX, impact G&A the periods million, was both G&A same our were XXXX. three our for internal both for in R&D primarily the to to compared The $XX.X for our XX, for our ended facility quarter by XX, adjustment XXXX million, July XXXX to in months

Operator? plan XXXX. runway operating With current our let’s the up third Our now the extends into cash quarter call that, for questions. of open

Operator

you Thank much. very

is from from question first Stifel. Ben Your Burnett

Your line open. is

Ben Burnett

to thank bit for provide Hey, as more maybe much color shift just for a questions. behind very and our I taking guess, you could timing GEN-XXX. little you the was I if what’s wondering

Chip Clark

Hey, production Ben, novel it’s marginal really given of actually Chip. a more It’s were Thanks we that it with beginning and plan of operating at the very when question. we small for drug broadly. how and the is a shift proud a set novel trial, the I’m this guidance

the to substantive in read nothing I month there’s about think into shift window. So one of this

Ben Burnett

in I maybe SITC terms what on guess, ask we’ll I of color just additional question, if other understood. more if curious get just GEN-XXX one you at offer data. could Okay, could

Chip Clark

you biomarker why just have to Tom, data and we’ll then Ben, don’t that the Yes. there. speak clinical and

Tom Davis

Chip. And for Ben. Thanks, thanks question, Sure. the

go to of excited data. good a We’re into with SITC amount

able certain responses the a has from degree. But two going be clinical And Of ago are questions course, perspective update already generate matured I to we’ll key and years for the to will certainly to that very were program responses able how and if think, long GEN-XXX we that elements program pleased. were we’re we’ll at persistent data any durable? was be last? clinical Additionally, the seeing in key immune that prolonged started and seen effect control, first, several be And disease the SITC they to those the immune were, program.

Jessica Flechtner

can posters free more some a this types on data, additional that provide we give And Jessica. like cell bit the little of that The of in immunophenotyping and color generating are is where biomarkers immunology include we DNA. we monitoring will T-cells the

Chip Clark

in in said the will these pleased we’re data to really degree which with the that. I Ben, differentiate we as And think continue to script,

Ben Burnett

Okay. Super interesting.

forward to looking We’re Thank it. you.

Chip Clark

Thank you.

Operator

[Operator Instructions] Your Gil Needham. next question with Blum is from

open. is line Your

Gil Blum

morning, for and good the thanks and everyone update. Hello

follow-up. Just should of on TiTAN a we some biopsy not and question have that at data I study, the have is expectation point. a the protocol of any part Or

Chip Clark

– to Gil, measure, to you post assume obviously, tumor. mean the infiltration for you clarify, example, mean this is T-cell into dosing just presumably biopsies, I Chip

Tom Davis

Exactly.

Chip Clark

you that handle question, Tom, Yes. don’t Okay. why please?

Tom Davis

Sure.

of infiltration The we require to tumor key the course, one TiTAN Of post our be going looking by biopsy endpoint are certainly protocol in and infusions. for – that a therapies tumor does a is cells. cell

have done. But that are As of with you can’t we certainly, biopsies around know, lot along cells. to data the patients data the we capturing activity a a probably be that the of other guarantee will able

Gil Blum

potentially All you different any business pursuing Inhibigen. development of there guys question. opportunity a Are ATLAS well? the the as right. And with maybe kind that with platform Are pathway

Chip Clark

is, Yes. important And yes. the Gil, answer question. it’s an

the both to demonstrate context be are would therefore oncology of in things as the want to you well treatment. We be we as of and T-cells for cancer right Inhibigens, finding reacting pro-tumor to in these to appear the therapies that context antigens which in preferentially continue certainly inclusion not

So opportunities this to in this. we progress are business able demonstrate on area and be to pursuing development hope

Gil Blum

Thank staying that’s it. and questions for taking and tune our Excellent. at you be we’ll

Chip Clark

Thank Great. you

Operator

Colleen Hanley [Operator a Instructions] Baird. question have We from from

Your line open. is

Colleen Hanley

our questions. Hi, taking good for morning. Thanks

are how be? able initial have update kind expect the of the you For update, patients the to on would to follow-up what tighten in you initial and comment many

Chip Clark

the Thank question, Colleen. Yes. for you

true specific excuse provide patients, the so we is window. make into GEN-XXX that realistically these the a provide we as going numbers very, think afford update our that not me, I is but to get bit that specifically of on sure possible. initial sense able to may guidance to provides, We’re here, A obviously may able more as much little very activity the sick to be and be goal as

Colleen Hanley

tumor this makes are if any And I know in there’s a Are sort any included there Thank be indicators that of you’re broad the study enrolling solid will types That faster? of tumors. sense. readout, enrolling initial range what in you.

Chip Clark

handle why please? Colleen’s don’t you Tom, question

Tom Davis

basket the to we focused study, is we’re particular to have pointed types with is on coming Sure. strength been sites but out, you selected known a certain those have and is, responsive Colleen, that as in does to be in tumor it the will space just prioritize that as patients tumor the down expansion specific line pointing specific are that a we the for inhibitors, focusing now Right study be checkpoint indication not we’re histology. categories cohorts, refractory. that allow we the would where in

Colleen Hanley

have you’ll that you. SITC, the Thank data autoimmune at Great. then on one diseases. last one in Inhibigen some And of the potential

Just that had share comments any thoughts autoimmune diseases? can wondered you on if you development on now and

Chip Clark

Yes. why take Yes. please? Jess, that It’s you really don’t question, interesting.

Jessica Flechtner

you Thank we would you beneficial want if the drive question. know, cancer, they that you since response. in autoimmunity, wondered cases showed for Inhibigen’s are of of we as We, kind where deleterious also be immune to that Yes. could in

that may these Inhibigen’s it so very dampening will at but be so is role and data shows And the data. we really that these very autoimmunity early, play excited a about early in presenting we’re SITC perhaps

Colleen Hanley

so Thanks questions. our much Great. for taking

Chip Clark

you, Thank Colleen.

Operator

time. further the turn Clark. back There would I to conference this at like Chip are no to question now

Chip Clark

operator. everyone today. us you, again And for thanks joining Thank

Operator

conference for call. Thank today’s participating. you concludes This

You may now disconnect.

Genocea Biosciences (GNCAQ) 28 Oct 212021 Q3 Earnings call transcript